知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.019 seconds)

    DNA cloning vectors with in vivo excisable plasmids
    2.
    发明授权
    DNA cloning vectors with in vivo excisable plasmids 失效
    具有体内可切除质粒的DNA克隆载体

    公开(公告)号：US5128256A

    公开(公告)日：1992-07-07

    申请号：US341261

    申请日：1989-04-20

    Applicant: William Huse ,  Joseph A. Sorge ,  Jay M. Short

    Inventor： William Huse ,  Joseph A. Sorge ,  Jay M. Short

    IPC: C12N15/64 ,  C12N15/70

    CPC classification number: C12N15/70 ,  C12N15/64

    Abstract: Vectors are described that circumvent traditional DNA cloning and subcloning procedures, and that contain a unique DNA cartridge that permits both cloning of DNA directly into DNA sequences present within the cartridge, and in vivo removal and circularization of the cartridge thereby yielding an autonomously replicating structure. Because the DNA cartridge can include a wide variety of functional DNA sequences, the cloned DNA can be subjected to a plethora of molecular biological procedures without having to remove the cloned DNA from the cartridge thereby obviating the need to perform additional subcloning techniques. A particularly useful example of this type of vector is bacteriophage lambda containing the DNA cartridge.

    Abstract translation: 描述了可以克服传统DNA克隆和亚克隆程序的载体，并且其含有独特的DNA柱，其允许将DNA直接克隆到存在于盒内的DNA序列中，并且在体内移除和环化圆筒，从而产生自主复制的结构。 因为DNA盒可以包括多种功能性DNA序列，所以克隆的DNA可以经受大量的分子生物学过程，而不必从盒中除去克隆的DNA，从而避免进行附加亚克隆技术的需要。 这种载体的特别有用的实例是含有DNA盒的噬菌体λ。

    Tumor specific human monoclonal antibodies and methods of use
    4.
    发明申请
    Tumor specific human monoclonal antibodies and methods of use 审中-公开
    肿瘤特异性人单克隆抗体及使用方法

    公开(公告)号：US20050003469A1

    公开(公告)日：2005-01-06

    申请号：US10910124

    申请日：2004-08-02

    Applicant: Jeffry Watkins ,  William Huse

    Inventor： Jeffry Watkins ,  William Huse

    IPC: A61K47/48 ,  C07K16/30 ,  G01N33/574 ,  C07K16/28

    CPC classification number: C07K16/3069 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/3015 ,  C07K16/3023 ,  C07K2317/21 ,  C07K2317/565

    Abstract: The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.

    Abstract translation: 本发明提供肿瘤特异性人单克隆抗体和功能片段。 还提供了编码肿瘤特异性人单克隆抗体和功能片段的核酸。 还提供了减少肿瘤细胞增殖的方法。 该方法包括施用有效量的肿瘤特异性人单克隆抗体或功能片段。 还提供了检测样品中的肿瘤细胞的方法。 该方法包括使细胞与肿瘤特异性单克隆抗体或功能片段接触并检测人单克隆抗体或功能片段与样品的特异性结合。

    Tnf-alpha binding molecules
    7.
    发明申请
    Tnf-alpha binding molecules 有权
    Tnf-α结合分子

    公开(公告)号：US20060269549A1

    公开(公告)日：2006-11-30

    申请号：US10541260

    申请日：2004-01-08

    Applicant: Jeffry Watkins ,  Alain Vasserot ,  David Marquis ,  William Huse

    Inventor： Jeffry Watkins ,  Alain Vasserot ,  David Marquis ,  William Huse

    IPC: A61K48/00 ,  A61K39/395 ,  A61K38/17

    CPC classification number: C07K16/241 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/92

    Abstract: The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-α and that are capable of neutralizing TNF-α at low concentrations. Preferably, the TNF-α binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

    Abstract translation: 本发明涉及TNF-α结合分子和编码TNF-α结合分子的核酸序列。 特别地，本发明涉及具有高结合亲和力，高缔合率，相对于人TNF-α的低解离速率且能够以低浓度中和TNF-α的TNF-α结合分子。 优选地，本发明的TNF-α结合分子包含具有完全人框架（例如人种系框架）的轻链和/或重链可变区。

    Method for identifying optimal binding ligands to a receptor
    8.
    发明申请
    Method for identifying optimal binding ligands to a receptor 审中-公开

    公开(公告)号：US20060194254A1

    公开(公告)日：2006-08-31

    申请号：US11219519

    申请日：2005-09-02

    Applicant: William Huse ,  Michael Freedman

    Inventor： William Huse ,  Michael Freedman

    IPC: C40B40/02 ,  C40B40/10

    CPC classification number: G01N33/566

    Abstract: The present invention provides a method for determining binding of a receptor to one or more ligands. The method consists of contacting a collective receptor variant population with one or more ligands and detecting binding of one or more ligands to the collective receptor variant population. The collective receptor variant population can be further divided into two or more subpopulations, one or more of the two or more subpopulations can be contacted with one or more ligands and one or more receptor variant subpopulations having binding activity to one or more ligands can be detected. The steps of dividing, contacting and detecting can be repeated one or more times. The invention also provides methods for identifying a receptor variant having optimal binding activity to one or more ligands. The invention additionally provides a method for determining binding of a ligand to one or more receptors. The method consists of contacting a collective ligand variant population with one or more receptors and detecting binding of one or more receptors to the collective ligand variant population. As with the variant receptor population, the methods for determining binding of a ligand to one or more receptors can include the steps of further dividing, contacting and detecting one or more ligand variants having binding activity to one or more receptors. The invention also provides methods for identifying a ligand or ligand variant having optimal binding activity.

    DNA cloning vectors with in vivo excisable plasmids
    9.
    发明授权
    DNA cloning vectors with in vivo excisable plasmids 失效
    具有体内可切除质粒的DNA克隆载体

    公开(公告)号：US5286636A

    公开(公告)日：1994-02-15

    申请号：US856556

    申请日：1992-05-21

    Applicant: William Huse ,  Joseph A. Sorge ,  Jay M. Short

    Inventor： William Huse ,  Joseph A. Sorge ,  Jay M. Short

    IPC: C12N15/64 ,  C12N15/70 ,  C12N15/10

    CPC classification number: C12N15/70 ,  C12N15/64

    Abstract: Vectors are described that circumvent traditional DNA cloning and subcloning procedures, and that contain a unique DNA cartridge that permits both cloning of DNA directly into DNA sequences present within the cartridge, and in vivo removal and circularization of the cartridge thereby yielding an autonomously replicating structure. Because the DNA cartridge can include a wide variety of functional DNA sequences, the cloned DNA can be subjected to a plethora of molecular biological procedures without having to remove the cloned DNA from the cartridge thereby obviating the need to perform additional subcloning techniques. A particularly useful example of this type of vector is bacteriophage lambda containing the DNA cartridge.

    Abstract translation: 描述了可以克服传统DNA克隆和亚克隆程序的载体，并且其含有独特的DNA柱，其允许将DNA直接克隆到存在于盒内的DNA序列中，并且在体内移除和环化圆筒，从而产生自主复制的结构。 因为DNA盒可以包括多种功能性DNA序列，所以克隆的DNA可以经受大量的分子生物学过程，而不必从盒中除去克隆的DNA，从而避免进行附加亚克隆技术的需要。 这种载体的特别有用的实例是含有DNA盒的噬菌体λ。

    Compositions and methods for producing enhanced antibodies
    10.
    发明申请
    Compositions and methods for producing enhanced antibodies 审中-公开
    用于产生增强型抗体的组合物和方法

    公开(公告)号：US20060204492A1

    公开(公告)日：2006-09-14

    申请号：US11439071

    申请日：2006-05-22

    Applicant: William Huse ,  Scott Glaser

    Inventor： William Huse ,  Scott Glaser

    IPC: A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06 ,  C07K16/44

    CPC classification number: C07K16/2848 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2319/00

    Abstract: The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αcβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. The invention additionally provides a high affinity LM609 grafted antibody comprising one or more CDRs having at least one amino acid substitution, where the αvβ3 binding activity of the high affinity LM609 grafted antibody is enhanced. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of αvβ3. The method consists of contacting αvβ3 with Vitaxin or a LM609 grafted antibody or functional fragments thereof under conditions which allow binding to αvβ3. Finally, the invention provides for a method of treating an αvβ3-mediated disease. The method consists of administering an effective amount of Vitaxin or a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to αvβ3.

    Abstract translation: 本发明提供了一种Vitaxin抗体和显示与α3β3的选择性结合亲和力的LM609接枝抗体。 维生素A抗体由至少一种维生素原重链多肽和至少一种维生素C轻链多肽或其功能片段组成。 还提供了维生素原重链和轻链多肽和功能片段。 LM609接枝抗体由至少一个CDR移植的重链多肽和至少一个CDR接枝的轻链多肽或其功能片段组成。 本发明另外提供了高亲和力LM609接枝抗体，其包含一个或多个具有至少一个氨基酸取代的CDR，其中高亲和力LM609的α3β3β3结合活性 接枝抗体增强。 编码维生素和LM609接枝的重链和轻链的核酸以及编码亲本非人抗体LM609的核酸。 类似地提供了这种编码核酸的功能性片段。 本发明还提供了抑制α3β3的功能的方法。 该方法包括在允许结合α睾丸激素的条件下，将α3β3β3和Vitaxin或LM609接枝抗体或其功能片段接触 3 。 最后，本发明提供了一种治疗α3β3介导的疾病的方法。 该方法包括在允许结合α3β3的条件下施用有效量的维生素或维生素LM609接枝抗体或其功能片段。

Patent Agency Ranking